X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (84) 84
humans (80) 80
male (59) 59
female (58) 58
cardiac & cardiovascular systems (57) 57
pulmonary hypertension (52) 52
middle aged (50) 50
abridged index medicus (47) 47
adult (44) 44
aged (36) 36
hypertension, pulmonary - drug therapy (36) 36
hypertension, pulmonary - physiopathology (33) 33
respiratory system (31) 31
hypertension (29) 29
therapy (24) 24
drug therapy (21) 21
pulmonary arterial hypertension (21) 21
survival (20) 20
cardiology (19) 19
double-blind method (19) 19
exercise (19) 19
treatment outcome (19) 19
care and treatment (17) 17
antihypertensive agents - therapeutic use (16) 16
hemodynamics (16) 16
research (16) 16
disease (15) 15
exercise test (15) 15
diagnosis (14) 14
double-blind (14) 14
adolescent (13) 13
cardiology and cardiovascular medicine (13) 13
cardiovascular (13) 13
hypertension, pulmonary - diagnosis (13) 13
pulmonary/respiratory (13) 13
bosentan (12) 12
follow-up studies (12) 12
pulmonary arteries (12) 12
dose-response relationship, drug (11) 11
medical colleges (11) 11
patients (11) 11
prostacyclin (11) 11
radiology, nuclear medicine & medical imaging (11) 11
ambrisentan (10) 10
critical care medicine (10) 10
heart (10) 10
physiological aspects (10) 10
prostacyclin analog (10) 10
tomography, x-ray computed (10) 10
angiography (9) 9
arterial-hypertension (9) 9
brain natriuretic peptide (9) 9
clinical trials (9) 9
controlled-trial (9) 9
exercise tolerance - drug effects (9) 9
heart failure (9) 9
mortality (9) 9
placebo-controlled trial (9) 9
studies (9) 9
usage (9) 9
aged, 80 and over (8) 8
cardiac catheterization (8) 8
continuous intravenous epoprostenol (8) 8
echocardiography (8) 8
health aspects (8) 8
peripheral vascular disease (8) 8
prognosis (8) 8
prospective studies (8) 8
scleroderma (8) 8
sitaxsentan (8) 8
tadalafil (8) 8
ultrafast computed-tomography (8) 8
analysis (7) 7
antihypertensive agents - administration & dosage (7) 7
complications and side effects (7) 7
coronary artery disease - diagnostic imaging (7) 7
drug therapy, combination (7) 7
endothelin (7) 7
epoprostenol - administration & dosage (7) 7
hemodynamics - drug effects (7) 7
hemodynamics - physiology (7) 7
hypertension, pulmonary - mortality (7) 7
internal medicine (7) 7
medicine & public health (7) 7
pulmonary (7) 7
quality of life (7) 7
reproducibility (7) 7
respiratory function tests (7) 7
severity of illness index (7) 7
sildenafil (7) 7
sulfonamides - therapeutic use (7) 7
time factors (7) 7
tomography, x-ray computed - methods (7) 7
coronary angiography - methods (6) 6
dosage and administration (6) 6
endothelin receptor antagonists (6) 6
exercise tolerance - physiology (6) 6
familial primary pulmonary hypertension (6) 6
hypertension, pulmonary (6) 6
hypertension, pulmonary - etiology (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Index Medicus | Abridged Index Medicus | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Life Sciences, ISSN 0024-3205, 12/2013, Volume 93, Issue 25-26, pp. e51 - e51
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 21, pp. 1971 - 1981
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 2010, Volume 5, Issue 12, pp. e14293 - e14293
Journal Article
Chest, ISSN 0012-3692, 08/2004, Volume 126, Issue 2, pp. 420 - 427
Journal Article
Advances in Pulmonary Hypertension, ISSN 1933-088X, 01/2018, Volume 16, Issue 4, pp. 165 - 169
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2017, Volume 126, pp. 84 - 92
Abstract Objective Pulmonary arterial hypertension (PAH) is a condition which may lead to right ventricular failure and premature death. While recent data... 
Pulmonary/Respiratory | Phosphodiesterase 5 inhibitor | Pulmonary Hypertension | Endothelin A receptor antagonist | Outcome assessment | Combination drug therapy | Ambrisentan | 5 INHIBITOR THERAPY | CARDIAC & CARDIOVASCULAR SYSTEMS | SILDENAFIL | METAANALYSIS | SAFETY | RANDOMIZED CONTROLLED-TRIAL | TADALAFIL | COMBINATION | ENDOTHELIN RECEPTOR ANTAGONIST | RESPIRATORY SYSTEM | ORAL TREPROSTINIL | BOSENTAN | Hypertension, Pulmonary - classification | Outcome Assessment (Health Care) | Humans | Middle Aged | Hypertension, Pulmonary - physiopathology | Male | Pyridazines - pharmacology | Exercise Tolerance - drug effects | Dose-Response Relationship, Drug | Tadalafil - administration & dosage | Natriuretic Peptide, C-Type - drug effects | Pyridazines - administration & dosage | Tadalafil - pharmacology | Adult | Female | Phenylpropionates - adverse effects | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Endothelin A Receptor Antagonists - therapeutic use | Pyridazines - adverse effects | Biomarkers - metabolism | Phenylpropionates - administration & dosage | Treatment Outcome | Antihypertensive Agents - therapeutic use | Survival | Phenylpropionates - pharmacology | Drug Therapy, Combination - methods | Elapid Venoms | Hemodynamics - drug effects | Medical colleges | Medical research | Care and treatment | Medicine, Experimental | Cardiology | Health aspects | Pulmonary hypertension | Complications and side effects | Endothelin | Drug therapy, Combination | Heart | Therapy | Chest | Physical training | Target recognition | Syngeneic grafts | Liver | pH effects | Incidence | Design | Connective tissues | Blood pressure | Diagnosis | Pulmonary arteries | Cut-off | Mortality | Committees | Frost | Physical fitness | Inhibitors | Blood circulation | Nitric oxide | Capillary pressure | Death | Toxins | Hemodynamics | Liver transplantation | Drugs | Diastolic pressure | Medical services | Clinical trials | Clinical outcomes | Contraction | Arteries | Guidelines | Ethics | Dyspnea | Safety engineering | Safety | Drug therapy | Heart diseases | Age | Hypertension | Brain natriuretic peptide | Receiving | Effectiveness | Statistical analysis | Wood | Pharmacology | Adhesion | Coronary artery disease | Nickel | Ventricle | Pharmacokinetics | Respiration | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2005, Volume 46, Issue 3, pp. 529 - 535
Journal Article
Journal Article
Advances in Pulmonary Hypertension, ISSN 1933-088X, 01/2019, Volume 18, Issue 2, pp. 42 - 46
Journal Article